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VP1uRed blood cells (RBCs) express abundantly parvovirus B19 receptor, and their role in the dissemination or
clearance of B19 infection is unknown. In this study, we report that in early, acute or persistent infection, B19
viremia is mostly associated with RBCs. The capacity of different patients' plasma or IgG to opsonize RBCs
collected from patients with early B19 infection, was investigated. The highest opsonization activity was
observed with plasma or IgG fractions from patients with past B19 infection. In contrast, IgG samples from
patients with acute or persistent infection showed no or little opsonization activity. The depletion of
antibodies speciﬁc to B19 VP1, but not VP2, from IgG samples, resulted in a signiﬁcant suppression of
opsonization. Furthermore, IgG samples preincubated with heated B19 particles exposing VP1-unique
(VP1u) region were unable to opsonize RBCs. These observations clearly suggest a role for anti-VP1u IgG in
the opsonization of RBC-bound B19 particles.© 2009 Elsevier Inc. All rights reserved.IntroductionHuman parvovirus B19 (B19) causes erythema infectiosum in
children (Anderson et al., 1983), and is also associated with a wide
spectrum of clinically symptoms, such as arthropathy (Reid et al.,
1985), anemia (Serjeant et al., 1981), myocarditis (Porter et al., 1988)
and hepatitis (Yoto et al., 1996). Parvovirus B19 capsid is composed of
the structural proteins, VP1 (minor, 5%) and VP2 (major, 95%), which
are identical except for the additional VP1-unique region (VP1u), at
the amino-terminal end of the VP1-protein (Cotmore et al., 1986;
Ozawa and Young, 1987). The most amino-terminal part of VP1u
region harbors strong neutralizing epitopes (Kurtzman et al., 1989a;
Anderson et al., 1995; Zufﬁ et al., 2001), whereas the carboxy-terminal
end of VP1u harbors a phospholipase A2 (PLA2)-like motif (Dorsch et
al., 2002), which is considered to play an important role in the
induction of inﬂammatory processes (Lu et al., 2006). These two
critical parts of VP1u have been shown to occupy an internal position
in the virion capsid, but a conformational change renders these
regions accessible (Ros et al., 2006).
Parvovirus B19 viremia has been shown to precede the appearance
of B19-speciﬁc IgM (Patou et al., 1993, Cassinotti et al., 1993), and to be
crucial for the early detection of B19 infection, especially in
immunocompromised patients (Marchand et al., 1999; Moreux et
al., 2002), and patients with hematological disorders (Mishra et al.,
2005). Furthermore, B19 DNA load has been shown to correlate with
the phase of infection (Manaresi et al., 2002), and its determination iseh@lycos.com (W. Chehadeh).
ll rights reserved.thought to be useful for monitoring persistent B19 infection in high-
risk group patients (Bergallo et al., 2006). Parvovirus B19 viremia has
been always investigated in serum or plasma of patients with B19
infection. However, in a recent study, the analysis of a blood sample
from one patient with recent B19 infection (IgM and IgG positive) has
revealed that more than 90% of the virions circulating in the blood
were associated to RBCs (Bönsch et al., 2008). Human mature red
blood cells (RBCs) express high levels of B19 receptor, the P antigen
(Fletcher et al., 1979), but are not permissive for parvovirus B19 entry
(Weigel-Kelley et al., 2003). Binding of B19 particles to RBCs has been
shown to expose the amino- and carboxy-terminal parts of VP1u
(Bönsch et al., 2008). The role of RBCs in the dissemination or
clearance of B19 infection is still unknown. In the current study, we
provide evidence that B19 viremia is mostly associated with RBCs, and
that RBC-bound B19 particles can be efﬁcaciously opsonized in vitro
by speciﬁc antibodies that are potentially directed against VP1u,
prevalent in patients with past B19 infection, and uncommon in
patients with persistent B19 infection.
Results
Parvovirus B19 infection in clinical samples
The characteristics of the study population are summarized in
Table 1. The frequencies of B19 DNA and B19-speciﬁc IgM and IgG
positivity in different plasma samples are given in Table 2. All patients
with detectable B19 DNA in plasma had detectable B19 DNA in RBC
fractions. Patients with B19 infection were grouped according to the
stage of infection, which was inferred from a combination of clinical
data and results of PCR and serology (Table 3). In either plasma or RBC
Table 1
Baseline characteristics of the study population.
Control
subjectsa
Patients with
fever and rashb
Patients with
chronic hemolytic
anemia
Kidney transplant
recipients with
aplastic crisis
n 100 138 162 40
Gender
M 63 (63%) 85 (62%) 96 (59%) 29 (72%)
F 37 (37%) 53 (38%) 66 (41%) 11 (8%)
Age (range)c
Children 7 (4–15) 7 (4–12) 6 (4–10) Null
Adults 40 (16–70) 40 (16–69) 45 (27–58) 52 (45–66)
a Control subjects included subjects tested negative for B19 DNA, IgM and IgG.
b Some patients with fever and rash have later developed arthralgia.
c Data are represented by the median of age in years.
Table 3
Number of patients grouped according to the stage of parvovirus B19 infection.
Stage of B19 infection B19-speciﬁc symptomsa B19-speciﬁc markers n
Early infection
(preseroconversion)
+ or − DNA+, IgM−, IgG− 20
Acute infection + DNA+, IgM+, IgG+ 15
Acute resolving infection + DNA−, IgM+, IgG+ 35
Past infection − DNA−, IgM−, IgG+ 31
Chronic infection + DNA+, IgM+ or−, IgG+ 14
a B19-speciﬁc symptoms included erythema over the malar areas, maculopapular
rash on the trunk and limbs, arthralgia, anemia-related symptoms or aplastic crisis.
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infection, whereas the lowest median viral load was observed in
resolving infection (Fig. 1A). The median B19 viral load in chronic
infection was signiﬁcantly higher than that in resolving infection
(pb0.0001), and signiﬁcantly lower than that in acute infection
(pb0.0001). Despite the fact that B19 viremia was mostly associated
with RBCs (Fig. 1B), a low but signiﬁcant correlation was obtained
between plasma and RBC viral load (r2=0.33, pb0.001, Fig. 1C).
Opsonization of RBCs isolated from patients with B19 infection
The capacity of different patients' plasma to opsonize RBC-bound
B19 particles (104 copies/RBC) isolated from patients with early B19
infection, was determined using erythrophagocytosis assay. As shown
in Fig. 2, the highest phagocytic index was observed when RBCs were
opsonized with plasma from patients with past B19 infection. The
opsonization activity of plasma in resolving B19 infection, was
variable between patients, but was signiﬁcantly higher than that in
acute (pb0.0001) or chronic B19 infection (pb0.0001). Plasma from
B19-seronegative control subjects and from patients with early B19
infection showed very low opsonization activity (Fig. 2).
Identiﬁcation of plasma opsonic factor
IgG eluted from plasma of patients with past B19 infection, showed
dose-dependent opsonization activity, whereas no signiﬁcant opso-
nization activity was observed using IgG eluted from plasma of B19-
seronegative subjects (Fig. 3A). To conﬁrm that the observed
opsonization was mediated through Fc-gamma receptors (FcγR),
monocytes were preincubated at 37 °C for 30 min with 0.01 μg/μl of
monoclonal IgG1 antibodies directed against FcγRI, FcγRII or FcγRIII.
Following removal of unbound antibodies by three times washing
with PBS, monocytes were used in the erythrophagocytosis assay. A
signiﬁcant impairment of erythrophagocytosis was observed with
anti-FcγRII and anti-FcγRIII antibodies (pb0.0001, Fig. 3B). The
inhibition of erythrophagocytosis was maximal when antibodies
against FcγRII and FcγRIII were mixed together before being added
to the monocytes. No signiﬁcant inhibition of erythrophagocytosisTable 2
Markers of parvovirus B19 infection in clinical plasma samples.
Condition n B19-DNA
positive-patients
n (%)
B19-speciﬁc IgM
positive-patients
n (%)
B19-speciﬁc IgG
positive-patients
n (%)
Fever and rash 138 17 (12) 21 (15) 32 (23%)
Chronic hemolytic
anemia
162 28 (17) 25 (15) 44 (27%)
Transient aplastic crisis
following kidney
transplantation
40 4 (10) 4 (10) 19 (47.5%)was observed when monocytes were preincubated with anti-FcγRI
antibodies or with the mouse IgG1 control.
Identiﬁcation of the target of opsonizing antibodies
In order to ascertain that opsonizing IgG recognize B19 particles
bound to the surface of RBCs, RBCs from patients with early B19
infection (104 B19 DNA copies/RBC), were treated with trypsin/EDTA
and washed with PBS prior to the erythrophagocytosis assay; trypsin/
EDTA treatment has been previously documented to remove com-
pletely the uninternalized B19 particles bound on the surface of RBCs
(Weigel-Kelley et al., 2003). As shown in Fig. 4A, no signiﬁcant
opsonization activity was detected following treatment of RBCs with
trypsin/EDTA. To conﬁrm these ﬁndings, RBCs from control subjects
were sensitized with 2×108 B19 copies/ml, and then used in the
erythrophagocytosis assay. A high percentage of phagocytic activity
was obtained in the presence of B19-sensitized RBCs, whereas no
signiﬁcant phagocytosis was observed in the presence of nonsensi-
tized RBCs (Fig. 4B).
In order to identify the target for the plasma IgG that mediate
opsonization of RBC-bound B19, IgG speciﬁc to B19 VP2 antigen were
depleted from IgG samples isolated from patients with past B19
infection, prior to their use in the erythrophagocytosis assay. The
results showed no signiﬁcant impairment in the opsonization activity
of IgG (Fig. 5A). The presence of anti-VP1 antibodies in IgG samples
depleted of anti-VP2 antibodies was conﬁrmed by western blot (Fig.
5B). However, when IgG speciﬁc to B19 VP1 were depleted from IgG
samples, a signiﬁcant inhibition of erythrophagocytosis was observed
(Fig. 5A). Western blot results showed no reactivity of IgG depleted of
anti-VP1 antibodies with VP1 protein (Fig. 5B). Unlike anti-VP1
antibodies, antibodies directed against denatured VP2 protein were
not detected by western blot, even before performing depletion tests.
Since the depletion of anti-VP1 antibodies but not anti-VP2 antibodies
resulted in the suppression of erythrophagocytosis, we investigated
whether or not VP1u is the target for opsonizing antibodies. The VP1u
region occupies an internal position in the native particles, and
becomes exposed by mild heat (Ros et al., 2006) or after B19 binding
to its receptor on RBCs (Bönsch et al., 2008). Parvovirus B19 particles
at 2×108 DNA copies/ml, were heated or not at 60 °C for 3 min to
allow maximal exposure of VP1u at the virion surface (Ros et al.,
2006), slowly cooled to 37 °C, and preincubated further at 37 °C for
30 min with 50 μg/ml of IgG samples isolated from patients with past
B19 infection. The ability of IgG samples to opsonize RBC-bound B19
particles was then tested using the erythrophagocytosis assay. The
results showed maximal suppression of erythrophagocytosis with IgG
samples preincubated with heated B19 particles, whereas 10–20%
suppression of erythrophagocytosis was observed with IgG samples
preincubated with unheated B19 particles (Fig. 5C).
Discussion
During the acute phase of infection, parvovirus B19 viremia usually
reaches a peak on days 7 to 9 and is resolved by the development of an
Fig. 1. Parvovirus B19 DNA load in plasma and red blood cell (RBC) fractions. (A)
Comparison of parvovirus B19 DNA load obtained by real-time PCR in plasma and RBCs
isolated from patients with parvovirus B19 infection at different stages of infection.
Horizontal bars represent median values. The two-tailed p-values were determined by
the Mann–Whitney U-test. (B) Percentage of B19 viremia in plasma and RBC fractions
from patients segregated according to the stage of B19 infection. Results are shown as
means±standard deviation. (C) Spearman correlation between plasma-associated B19
viral load and RBC-associated B19 viral load.
Fig. 2. Evaluation of the ability of plasma from patients at different stages of parvovirus
B19 infection to opsonize red blood cells isolated from patients with early B19 infection.
Red blood cells containing 104 B19 DNA copies/cell, were preincubated for 30 min at
37 °C with decomplemented and adsorbed plasma from control subjects or patients,
and then added to monocyte cultures obtained from healthy subjects. Following lysis of
noninternalized red blood cells, phagocytosis of red blood cells by monocytes was
assessed by a colorimetric assay. Horizontal bars represent median values.
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(Anderson et al., 1985). Parvovirus B19 viremia can also be detected
late in some immunocompetent patients despite the development of
B19-speciﬁc IgG (Cassinotti and Siegl, 2000). The current study
showed that most B19 viremia in the blood is associated with RBCs,
even in the absence of speciﬁc IgM and IgG antibodies which may
neutralize plasma B19 virions. The detection of RBC-associated
viraemia during convalescence phase indicates that the complete
clearance of B19 viremia may take longer time than expected. Human
RBCs, which express high levels of B19 receptor (Fletcher et al., 1979),
bind B19 virus but do not allow viral entry (Weigel-Kelley et al., 2003).
The role of RBCs in the dissemination or clearance of B19 virions is
unknown. The erythrophagocytosis assay, described here, has pre-
viously been used to assess the immune response to malaria infection
(Groux and Gysin, 1990, Mota et al., 1998) and HIV infection (Chan et
al., 2001, Kedzierska et al., 2001, Azzam et al., 2006). It was also used to
investigate the role of commercial immunoglobulins in the inhibition
of autoantibody-mediated erythrophagocytosis (Léonard et al., 2006).
Using the erythrophagocytosis assay, we showed, for the ﬁrst time,
that in addition to the hemagglutination properties of B19 particles
(Brown and Cohen, 1992), B19 virus may cause erythrophagocytosis
mediated by speciﬁc opsonizing antibodies. This opsonization was
independent of complement system, since all plasmawere inactivated
by heat treatment, and since opsonization activity was suppressed
when IgG were depleted from plasma by afﬁnity chromatography.
Furthermore, the opsonization of RBC-bound B19 particles was
suppressed in the presence of anti-FcγRII and anti-FcγRIII antibodies,
which bind IgG in the form of immune complexes (Gessner et al.,
1998).
Parvovirus B19 VP1 and VP2 proteins originate from overlapping
reading frames, and are identical except for 227 residues on the amino
terminus of VP1, which form the VP1u region. The detection of anti-
VP1 antibodies, but not anti-VP2 antibodies, in the opsonizing IgG, by
western blot, strongly suggests a role for anti-VP1 antibodies in the
opsonization of RBC-bound B19 particles. However, the results of
western blot assay cannot exclude the presence of antibodies raised
against undenatured VP2 in clinical specimen from patients with past
B19 infection, since the immune response to B19 is characterized by a
gradual loss of antibodies directed against linear epitopes of VP2
(Söderlund et al., 1995; Franssila et al., 1996). The absence of
Fig. 3. Opsonization of red blood cells from patients with B19 infection is mediated by
speciﬁc IgG. (A) IgG eluted from plasma by afﬁnity chromatography, were preincubated
at different concentrations with red blood cells containing 104 B19 DNA copies/cell, and
then added to monocytes from healthy subjects to assess their opsonization activity
using the erythrophagocytosis assay. Results are shown as means±standard deviation
of ﬁve separate measurements. (B) Plasma IgG (50 μg/ml) from patients with past B19
infection were preincubated with red blood cells containing 104 B19 DNA copies/cell,
and then added to monocytes preincubated with 0.01 μg/μl of monoclonal IgG1
antibodies directed against FcγRI, FcγRII and FcγRIII. Mouse IgG1 was used as isotypic
control in each experiment. Phagocytosis of red blood cells by monocytes was assessed
by a colorimetric assay.
Fig. 4. Parvovirus B19 particles bound to red blood cells are recognized by speciﬁc
opsonizing antibodies. (A) Red blood cells containing 104 B19 DNA copies/cell from
patients with early B19 infection, were treated or not with trypsin/EDTA, prior to their
incubation with 50 μg/ml of IgG from patients with past B19 infection. Opsonization of
red blood cells was then assessed on monocyte cultures using the erythrophagocytosis
assay. (B) Red blood cells from healthy subjects were sensitized with 2×108 B19 copies/
ml or with culture media, and then incubated, after removal of unbound B19 particles,
with 50 μg/ml of IgG samples from patients with past B19 infection. Sensitized and
nonsensitized RBCs were then added tomonocyte-containing wells. Phagocytosis of red
blood cells by monocytes was assessed by a colorimetric assay. Results are shown as
means±standard deviation of ﬁve separate measurements.
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samples directed against recombinant VP2 protein expressed in
baculovirus system (Brown et al., 1990a, 1990b), suggests that anti-
VP2 antibodies do not exert opsonization activity against RBC-bound
B19 particles. The detection of anti-VP1 antibodies in the opsonizing
IgG depleted of anti-VP2 antibodies, and the suppression of
erythrophagocytic activity after depletion of IgG samples on insect
cells expressing recombinant VP1 protein (Brown et al., 1990a,1990b),
suggest that VP1u is the potential target for opsonizing antibodies.
VP1u region has been shown to be steadily exposed on the surface
of RBCs preincubated with B19 particles (Bönsch et al., 2008), which
explains the high opsonization activity obtained after incubation of
RBC-bound B19 particles with IgG samples. In free B19 particles, the
most N-terminal part of VP1u which harbors strong neutralizing
epitopes, and the PLA2-like motif at the C-terminal region of VP1u,
occupy an internal position in the capsid (Ros et al., 2006, Bönsch et
al., 2008). Heating B19 particles at 60 °C has been shown to result in
maximal exposure of VP1u at the surface of B19 particles (Ros et al.,
2006). Our results showed a signiﬁcant depletion of opsonizing
antibodies after preincubation of IgG samples with heated B19particles, suggesting that the N-terminal part and/or C-terminal
part of VP1u region is involved in the opsonization of RBC-bound B19.
The partial depletion of opsonizing antibodies obtained after
preincubation of IgG samples with unheated B19 particles, may be
explained by speciﬁc binding to a region of VP1u between the N- and
C-terminal, which is exposed on the surface of unheated B19 particles.
These observations are in linewith a previous report showing that B19
virions in human serum could be immunoprecipitated by using rabbit
antisera raised against the entire VP1u (Rosenfeld et al., 1992).
However, our results cannot exclude the presence of another
opsonizing antigen than VP1u, which needs to be identiﬁed.
The impaired opsonization activity of acute plasma specimen
containing anti-VP1 and anti-VP2 antibodies, and the enhanced
opsonization activity of plasma from past B19 infection, suggest a
slow development of anti-VP1u opsonizing antibodies. Previous
reports have shown that antibody speciﬁcity to the VP2 protein
predominates in early B19 infection, whereas the VP1u antibody
speciﬁcity predominates late during convalescence phase (Kurtzman
et al., 1989a). Furthermore, in immunocompromised patients, persis-
tent parvovirus B19 infections may occur despite the presence of
circulating B19 antibody (Schleuning et al., 1999; Moreux et al., 2002;
Fattet et al., 2004). Similarly, the current study showed that, in spite of
having speciﬁc anti-B19 VP1 and VP2 antibodies, plasma frompatients
with persistent B19 infection did not mediate high opsonization
activity compared to plasma from patients with past B19 infection.
Thus, only antibodies obtained from immune individuals were able to
Fig. 5. Parvovirus B19 VP1u region is a potential target for opsonizing antibodies. (A)
Antibodies against B19 VP1 or VP2 antigenwere depleted from opsonizing IgG samples,
by adsorption on insect cells expressing recombinant VP1 or VP2 antigen, respectively.
The ability of depleted IgG samples to opsonize RBCs from patients with early B19
infection was assessed on monocyte cultures using the erythrophagocytosis assay. (B)
Western blot analysis showing the speciﬁcity of opsonizing IgG puriﬁed from 3 patients
with past B19 infection, before depletion (lanes A–C), after depletion on insect cells
expressing recombinant VP2 protein (lanes D–F), and after depletion on insect cells
expressing recombinant VP1 protein (lanes G–I). (C) B19 particles at 2×108 DNA
copies/ml, were heated or not to allow maximal exposure of VP1u at the surface of B19
particles, and then preincubated with 50 μg/ml of IgG samples isolated from patients
with past B19 infection. The ability of B19- or medium-treated IgG samples to opsonize
RBC-bound B19 particles, was then assessed on monocyte cultures using the
erythrophagocytosis assay. Results are shown as means±standard deviation of ﬁve
separate measurements.
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for opsonizing antibodies against recurrent B19 infection. The
decreased opsonization activity of plasma from persistent B19
infection may be due to the absence of development of enoughamounts of speciﬁc antibodies directed against VP1u region. These
observations are in agreement with previous reports showing a poor
immune response against VP1u in persistent B19 infections (Kurtz-
man et al., 1989a). It is noteworthy that immunoglobulin preparations
have been used to treat persistent (Kurtzman et al., 1989b) and acute
B19 infection (Herzog-Tzarfati et al., 2006). They contain anti-B19
antibodies which showed speciﬁcities to both VP1 and VP2 capsid
proteins (Kurtzman et al., 1989a). It would therefore be of consider-
able interest to determine the amount of opsonizing antibodies in the
commercial immunoglobulins, and therefore to be able to predict
which immunoglobulin preparation can be of therapeutic value.
Furthermore, opsonizing antibodies have been shown to correlate
with their protective capacity in vaccination studies (Kaufman et al.,
1986; Perraut et al., 1995; Schwenk et al., 2003). The current study
suggests that a successful vaccine against parvovirus B19 infection,
should be based on the induction of opsonizing antibodies directed
against VP1u.
While opsonizing antibodies appear to exert protective role against
recurrent B19 infection, they may also have harmful effects. Indeed,
antibody opsonization of RBC-bound B19 particles may precipitate
severe anemia in patients with hematological disorders who develop
recurrent B19 infection. Furthermore, parvovirus B19 has been
associated with the development of hemophagocytic syndrome
(HPS), characterized by pancytopenia and inﬁltration of bone marrow
and various organs, by histiocytes which are actively involved in
hemophagocytosis (Watanabe et al., 1994; Sato et al., 1999; Larroche
et al., 2002; Dutta et al., 2005; Yilmaz et al., 2006). Whether antibody
opsonization of RBC-bound B19 particles can cause, precipitate or
exacerbate HPS is unknown.
In this study, we have shown that B19 viremia was mostly
associated with RBCs, and that RBC-bound B19 particles may be
opsonized by speciﬁc anti-VP1 IgG antibodies isolated from patients
with resolving or past B19 infection. Opsonization assay appears as an
additional immunological tool to distinguish between immune and
non-immune individuals. The unability of patients with persistent B19
infection to clear the virus may be related to a defect in the production
of speciﬁc opsonizing antibodies directed against VP1u region. The
production of opsonizing antibodies in persistent parvovirus B19
infection should be investigated in high number of patients to better
understand the development of immunity to B19 infection. Further-
more, the IgG subclass involved in the opsonization activity needs to
be identiﬁed since a balance between IgG subclasses may determine
whether or not a plasma specimen can opsonize RBC-bound B19
particles.
Materials and methods
Collection of clinical samples
The clinical specimens for this study were received during the
period between September 2006 and October 2008. Venous blood
specimens were collected in 5 ml EDTA tubes from patients suffering
from fever and rash followed or not with arthralgia (97 children, 41
adults), or from chronic hemolytic anemia (92 children, 70 adults).
They were enrolled from outpatient departments of Farwaniya,
Mubarak Al-Kabeer, and Al-Sabah hospitals. Blood specimens were
also collected from 40 kidney transplant recipients with transient
aplastic crisis (TAC). They were recruited from Hamad El-Essa Organ
Transplant Center (OTC), and were receiving immunosuppressive
drugs at the time of the study. Blood samples tested positive for
cytomegalovirus (CMV) DNA, Epstein–Barr virus (EBV) IgM, human
herpes virus type 6 (HHV-6) DNA, rubella virus IgM, measles virus
IgM, adenoviral DNA, or enteroviral RNA were excluded from this
study. The control group included 100 control subjects tested negative
for B19 DNA, IgM and IgG. They had no fever or any disease known to
be associated with viral infection. The ethical permission on this
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Research Administration, Faculty of Medicine, Kuwait University.
Virus and antibodies
Serum samples containing high titers of parvovirus B19 DNA were
obtained in our laboratory in the course of routine virological
screening. They were isolated from B19-infected patients during the
early viremic phase, and tested negative for B19-speciﬁc IgM and IgG
antibodies. Ten ml of B19-containing serum samples was diluted 1:2
in phosphate-buffered saline (PBS, pH 7.4), and preincubated over-
night at 4 °C with protein L and G agarose beads (Santa Cruz
Biotechnology, Santa Cruz, CA) to remove immunoglobulins and
immunocomplexes. After centrifugation at 1000 ×g for 5min, the B19-
containing supernatant was clariﬁed by centrifugation on a Macro-
sep® 300 kDa Omega membrane (Pall Life Sciences, Ann Arbor, MI),
and resuspended in 1 ml PBS, pH 7.4. Parvovirus B19 DNA load was
obtained by quantitative real-time PCR as described below. Mono-
clonal IgG1 neutralizing anti-human FcγRI (CD64) clone 10.1,
monoclonal IgG1 neutralizing anti-human FcγRII (CD32) clone
AT10, monoclonal IgG1 neutralizing anti-human FcχRIII (CD16)
clone DJ130c, and mouse IgG1 negative control were purchased
from AbD Serotec (MorphoSys UK Ltd, Oxford, UK).
Blood cell separation
Plasma and mononuclear cells (MNCs) were separated from blood
samples by centrifugation on a Ficoll-Paque™ Plus density gradient
(GE HealthCare Bio-Sciences, Uppsala, Sweden). Monocytes were
negatively isolated from MNCs of control subjects by depletion of
other blood cells using speciﬁc immunomagnetic beads (Dynal
Monocyte Negative Isolation Kit, Invitrogen Dynal AS, Oslo, Norway).
They were resuspended in serum-free RPMI 1640 medium supple-
mented with 2 mM L-glutamine, seeded at 5×104 cells per well into
96-well ﬂat-bottom tissue culture plates, and allowed to adhere for
60 min at 37 °C before being used in the erythrophagocytosis assay.
Red blood cells (RBCs) from patients and controls were collected and
washed three times with PBS, pH 6.7, and resuspended at a
concentration of 5×106 RBCs/ml in an isotonic salt solution (Alsever's
solution, Sigma Aldrich, St. Louis, MO). Red blood cell suspensions
were kept stored at 4 °C until further use (up to 2 weeks).
Detection of B19-speciﬁc IgM and IgG
The seroprevalence of B19 infection in patients and control
subjects was determined by detecting plasma B19-speciﬁc IgM and
IgG using immunoﬂuorescence assays (IFA) from PanBio (PanBio Inc,
Baltimore, Maryland) and Biotrin (Biotrin International, Dublin,
Ireland) as described by the manufacturers' instructions. The PanBio
tests were based on the detection of antibodies directed against
recombinant B19 VP2 antigen, and the Biotrin test on the detection of
antibodies directed against recombinant B19 VP1 antigen. A plasma
samplewas considered B19 antibody positive if it was reactive on both
tests.
Detection and quantiﬁcation of B19 DNA
Total DNA was extracted from 140 μl of plasma samples and from
5×105 RBCs using Qiamp® DNA Blood Mini kit (QIAGEN Inc.,
California, USA), as described by the manufacturer's instructions.
The B19 DNAwas ampliﬁed by nested PCR using previously described
primers and conditions (Candotti et al., 2004). The PCR reaction was
carried out with a Perkin-Elmer Applied Biosystems Gene-Amp 9700
thermocycler. Parvovirus B19 DNA cloned into pGEM®-T Easy vector
(Promega Corporation, Madison, WI), was used as positive control.
The B19 viral load was determined on the LightCycler® 2.0 Real-TimePCR system by using the Parvovirus B19 Quantiﬁcation Kit (Roche
Molecular Biochemicals). As noted in the manufacturer's instructions,
the parvovirus variants A6 and V9 are not detectedwith this assay. The
linear range of the assay was from 102 to 106 copies per reaction.
Erythrophagocytosis assay
One ml of plasma from control subjects or patients, was heated at
56 °C for 30 min to inactivate complement components. To prevent
unspeciﬁc binding to RBCs, 1 ml of decomplemented plasma was
adsorbed at room temperature for 30 min, with 0.5 ml of normal
human RBC pool prepared by mixing equal volume of RBCs from B19-
seronegative control subjects with different blood group. RBC
suspensions obtained from patients with early B19 infection at
preseroconversion phase, were washed three times with PBS, and
then resuspended at 5×106 RBCs/ml in PBS pH 6.7, containing 3%
bovine serum albumin (BSA). B19 viral load in RBC suspension was
measured by real-time PCR, and the number of RBCs used for
erythrophagocytosis assay was adjusted to contain 104 B19 DNA
copies/RBC. In some experiments, RBC suspensions were treated with
trypsin-EDTA (0.05% trypsin plus 0.02% EDTA) for 5 min at 37 °C to
remove B19 particles from the surface of RBCs as described previously
(Weigel-Kelley et al., 2003). One hundred μl of RBC suspension was
preincubated with 100 μl of decomplemented and adsorbed plasma
for 30 min at 37 °C in a shaking waterbath. RBCs were then washed 3
times with 5 ml PBS, resuspended in 100 μl of serum-free RPMI 1640
medium supplemented with 2 mM L-glutamine and 2 μM β-
mercaptoethanol, and then added to the monocyte-containing wells.
Phagocytosis of RBCs was terminated after 1 h incubation at 37 °C and
5% CO2, by placing the plate on ice, and the wells were washed
thoroughly with cold PBS to remove unbound RBC. Adhered but non-
phagocytosed RBCs were lysed with 0.2% NaCl solution for 3 min, and
removed by washing three times with prewarmed RPMI 1640
medium. Monocytes were then lysed with 6 mol/L urea solution
containing 0.2 mol/L Tris–HCl buffer pH 7.4. The number of
internalized RBCs was determined using previously described colori-
metric assay (Gebran et al., 1992). In brief, 10 mg/ml of 2,7-
diaminoﬂuorene (Sigma Aldrich) was added, and the absorbance at
620 nm, which is proportional to the amount of ﬂuorene blue released
in the presence of the pseudoperoxidase activity of hemoglobin, was
measured. The number of phagocytosed RBCs was determined by
extrapolation from a standard curve generated using known amounts
of RBCs (ranging from 5×103 to 5×106). The number of RBCs
phagocytosed per 100 monocytes, usually referred to as phagocytic
index, was obtained by dividing the number of phagocytosed RBCs by
the number of monocytes in the well (5×104 cells), and multiplied
by 100.
IgG afﬁnity puriﬁcation
Plasma samples (2 ml) collected from patients with past B19
infection or from B19-seronegative subjects, were decomplemented
and adsorbed with 1 ml of normal human RBC pool as described
above. They were then diluted twofold with PBS at pH 7.0, ﬁltered
(0.45 μm), and passed at a ﬂow rate of 0.1 ml/min over a
1.6 cm×20 cm column of Protein G-Sepharose™ Fast Flow (GE
Healthcare) equilibrated with PBS buffer. The column was then
washed extensively with the same buffer until the absorbance at
280 nm of the efﬂuent was zero. Elution of IgG was performed at a
ﬂow rate of 1 ml/minwith elution buffer containing 0.1 M glycine HCl
pH 2.5. To preserve the activity of acid-labile IgG, the eluted fractions
were neutralized by adding 100 μl of 1 M Tris–HCl, pH 7.4 to each
milliliter of eluted ﬂuid. Eluted IgGwas concentrated using Biomax-30
membrane (Millipore Corp., Bedford, MA) according to the manufac-
turer's instructions. IgG concentrations were estimated using an
assumed extinction coefﬁcient of 1.43 for 1 mg/ml solution at 280 nm.
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One hundred μl of RBCs from healthy subjects was preincubated for
2 h at 4 °C with 100 μl of B19 virus at 2×108 DNA copies/ml. After
excessive washing with PBS to remove unbound B19 particles,
sensitized RBCs were resuspended in 100 μl of PBS, and a fraction
was used to quantify RBC-associated B19 by real-time PCR. Sensitized
RBCs with a B19 viral load of 104 copies/RBC were then used in the
erythrophagocytosis assay described above.
Depletion of anti-parvovirus B19 VP1 and VP2 antibodies
Fifty μl of puriﬁed plasma IgG (50 μg/ml) from patients with past
B19 infection, was added either to the well slides coated with insect
cells expressing parvovirus B19 recombinant VP1 antigen (Biotrin
International), or to the well slides coated with insect cells expressing
parvovirus B19 recombinant VP2 antigen (PanBio® Inc). Following
30 min incubation at 37 °C in a moist chamber, IgG samples were
harvested from the well slides and tested for their ability to opsonize
RBC-bound B19 using the erythrophagocytosis assay.
Western blot analysis
Ten μl of parvovirus B19 suspension, prepared as described above,
was added to 20 μl of Laemmli sample buffer (Bio-Rad Laboratories,
Hercules, CA) containing 2% β-mercaptoethanol, and heated at 100 °C
for 5min, before being loaded into 12% SDS-polyacrylamide gel. One μl
of the Precision Plus Protein™ Standards marker (Bio-Rad Labora-
tories) was dissociated in the same way, and applied to the left side of
the gel. Following electrophoresis using the Mini-Protean® Tetra Cell
(Bio-Rad Laboratories), the separated proteins were electroblotted
onto a nitrocellulosemembrane (Bio-Rad Laboratories) using theMini
Trans-Blot® Electrophoretic Transfer Cell (Bio-Rad Laboratories), and
then blocked with Tris-buffered saline (TBS) buffer pH 7.5, containing
3% gelatin, at room temperature for 1 h. Following washing with TBS
buffer containing 0.05% (v/v) Tween-20, the membrane was cut into
strips, and each strip was incubated, for 1 h at room temperature, with
opsonizing IgG sample diluted at 1:50 in TBS buffer containing 1%
gelatin and 0.05% (v/v) Tween-20. The reactivity of human IgG with
parvoviral proteins was detected using the Immun-Blot goat anti-
human IgG (H+L) alkaline phosphatase assay kit (Bio-Rad Labora-
tories) according to the manufacturer's instructions.
Statistical analysis
Mann–Whitney U-test was used to compare median values.
Spearman's rank test was used to investigate the correlation between
plasma-associated viral load and RBC-associated viral load. Probability
levels less than 0.05 by the two-tailed test were considered signiﬁcant.
All statistical analyses were performed using SPSS 15.0 software for
Windows (SPSS, Inc., Chicago, IL).
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